Discussions that mention bupropion

Smoking Cessation board

Here is the regimen for using wellbutrin for smoking cessation, according to the mfr.
"Treatment for Smoking Cessation

Usual Dosage for Adults: The recommended and maximum dose of bupropion HCl sustained release tablets for smoking cessation is 300 mg/day, given as 150 mg twice daily. Dosing should begin at 150 mg/day given every day for the first 3 days, followed by a dose increase for most patients to the recommended usual dose of 300 mg/day. There should be an interval of at least 8 hours between successive doses. Doses above 300 mg/day should not be used (see WARNINGS). Treatment with bupropion HCl sustained release tablets should be initiated while the patient is still smoking, since approximately 1 week of treatment is required to achieve steady-state blood levels of bupropion. Patients should set a "target quit date" within the first 2 weeks of treatment with bupropion HCl, generally in the second week. Treatment with bupropion HCl should be continued for 7 to 12 weeks; duration of treatment should be based on the relative benefits and risks for individual patients. If a patient has not made significant progress toward abstinence by the seventh week of therapy with bupropion HCl, it is unlikely that he or she will quit during that attempt, and treatment should probably be discontinued. Dose tapering of bupropion is not required when discontinuing treatment. It is important that patients continue to receive counseling and support throughout treatment with bupropion, and for a period of time thereafter.

Individualization of Therapy: Patients are more likely to quit smoking and remain abstinent if they are seen frequently and receive support from their physicians or other health care professionals. It is important to ensure that patients read the instructions provided to them and have their questions answered. Physicians should review the patient's overall smoking cessation program that includes treatment with bupropion HCl. Patients should be advised of the importance of participating in the behavioral interventions, counseling, and/or support services to be used in conjunction with bupropion HCl. See information for patients at the end of the package insert.

The goal of therapy with bupropion HCl is complete abstinence. If a patient has not made significant progress towards abstinence by the seventh week of therapy with bupropion HCl, it is unlikely that he or she will quit during that attempt, and treatment should be discontinued.

Patients who fail to quit smoking during an attempt may benefit from interventions to improve their chances for success on subsequent attempts. Patinets who are unsuccessful should be evaluated to determine why they failed. A new quit attempt should be encouraged when factors that contributed to failure can be eliminated or reduced, and conditions are more favorable.

Maintenance: Although clinical data are not available regarding the long-term use (>12 weeks) of bupropion for smoking cessation, bupropion has been used for longer periods of time in the treatment of depression. Whether to continue treatment with bupropion HCl for periods longer than 12 weeks for smoking cessation must be determined for individual patients.

Combination Treatment with Bupropion HCl and a Nicotine Transdermal System (NTS): Combination treatment with bupropion HCl and NTS may be prescribed for smoking cessation. The prescriber should review the complete prescribing information for both bupropion HCl and NTS before using combination treatment. See also CLINICAL STUDIES for methods and dosing used in the bupropion HCl and NTS combination trial. Monitoring for treatment-emergent hypertension in patients treated with the combination of bupropion and NTS is recommended."